Hypertensive disorders of pregnancy are among the leading causes of maternal and perinatal morbidity and mortality worldwide, complicating approximately 10% of all pregnancies.1 The pharmacological management of hypertension in pregnancy is uniquely constrained: the clinician must simultaneously protect the mother from the immediate risks of severe hypertension while avoiding agents that harm the developing fetus.
Several of the most effective antihypertensive drug classes used in the general population are absolutely contraindicated in pregnancy, and the evidence base for safe alternatives is derived largely from smaller trials and decades of observational data rather than from the large outcome trials that anchor general hypertension pharmacology. This module covers the classification of hypertensive disorders in pregnancy, the physiological changes in blood pressure (BP) during normal pregnancy, the pharmacological agents proven safe and effective for use in pregnancy, the management of acute severe hypertension in pregnancy, and postpartum considerations.
The American College of Obstetricians and Gynecologists (ACOG) and most major guidelines recognize four categories of hypertensive disorders in pregnancy.1,2
Chronic hypertension is defined as hypertension that predates pregnancy or is diagnosed before 20 weeks of gestation (systolic blood pressure [SBP] ≥140 mmHg or diastolic blood pressure [DBP] ≥90 mmHg). It affects approximately 1–5% of pregnancies in the United States. Patients with chronic hypertension (HTN) are at substantially higher risk of superimposed preeclampsia (20–25% incidence versus 3–5% in normotensive women). BP often falls physiologically during the second trimester, which may allow dose reduction of antihypertensive medications. Antihypertensive therapy must be switched to pregnancy-safe agents prior to or immediately upon confirmation of pregnancy.
Gestational hypertension is new onset of hypertension (SBP ≥140 or DBP ≥90 mmHg) at or after 20 weeks of gestation in the absence of proteinuria or other features of preeclampsia. It accounts for approximately 6% of pregnancies and resolves within 12 weeks postpartum by definition. Women with gestational HTN have a 15–25% risk of developing preeclampsia and are at increased long-term risk of chronic hypertension (approximately 50% develop HTN within 10 years). Management requires antihypertensive therapy for severe-range BP and close monitoring for progression to preeclampsia.
Preeclampsia is defined as new onset of hypertension (≥140/90 mmHg) at or after 20 weeks of gestation, accompanied by one or more of the following: proteinuria (≥300 mg/24 hours, or protein:creatinine ratio ≥0.3, or dipstick 2+ on two occasions); thrombocytopenia (platelet count <100,000/mcL); renal insufficiency (creatinine >1.1 mg/dL or doubling of creatinine in the absence of other renal disease); impaired liver function (elevated transaminases twice the upper limit of normal; right upper quadrant or epigastric pain); pulmonary edema; or new-onset headache unresponsive to medication in the absence of alternative diagnoses, or visual disturbances.1 An important update: proteinuria is no longer required for the diagnosis of preeclampsia if other severe features are present.
The pathophysiology of preeclampsia begins with abnormal placentation and failure of physiological trophoblastic invasion of the spiral arteries, leading to placental ischemia. Placental ischemia causes release of anti-angiogenic factors, specifically soluble fms-like tyrosine kinase-1 (sFlt-1), that inhibit vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). Systemic endothelial dysfunction follows: vasoconstriction, increased vascular permeability, platelet activation, and coagulation cascade activation. The end result is maternal hypertension, proteinuria, and multi-organ involvement.
Severe features of preeclampsia (any one qualifies) include: SBP ≥160 or DBP ≥110 mmHg on two occasions at least 4 hours apart; thrombocytopenia (<100,000/mcL); renal insufficiency (creatinine >1.1 mg/dL); impaired liver function (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >2× upper limit of normal [ULN]) with or without right upper quadrant pain; pulmonary edema; or new-onset headache unresponsive to acetaminophen or visual symptoms.
HELLP syndrome represents a severe form of preeclampsia characterized by hemolysis (H): microangiopathic hemolytic anemia, elevated lactate dehydrogenase (LDH), and schistocytes on peripheral blood smear; elevated liver enzymes (EL): AST and ALT >2× ULN; and low platelets (LP): <100,000/mcL (severe: <50,000/mcL). HELLP may occur without severe hypertension; BP can be only mildly elevated or even normal in 15–20% of cases, which is why diagnosis requires vigilance beyond BP measurement. Management includes delivery as definitive treatment, corticosteroids for fetal lung maturity if <34 weeks, magnesium sulfate for seizure prophylaxis, and antihypertensive therapy for BP control.
Eclampsia is defined as new-onset grand mal seizure in a woman with preeclampsia without another identifiable cause. It can occur antepartum (most common), intrapartum, or postpartum (up to 48 hours after delivery, rarely up to 4 weeks postpartum). Magnesium sulfate is the agent of choice for both seizure prophylaxis in severe preeclampsia and for treatment of eclamptic seizures; it is not an antihypertensive, and BP management with appropriate antihypertensives must proceed in parallel. Recurrent eclamptic seizures despite magnesium warrant addition of a benzodiazepine or phenytoin/levetiracetam; delivery is the definitive treatment.
Understanding the normal physiology of BP during pregnancy is essential for interpreting clinical findings and avoiding both over- and under-treatment.2 In the first trimester, progesterone-mediated vasodilation causes a fall in systemic vascular resistance (SVR), and BP typically begins to decline. In the second trimester, maximal physiological vasodilation is reached; BP arrives at its nadir, with SBP falling 5–10 mmHg and DBP falling 10–15 mmHg below preconception levels. Cardiac output increases substantially through increased heart rate and stroke volume. This nadir can mask pre-existing hypertension and obscure early development of preeclampsia.
In the third trimester, BP begins to rise toward preconception levels by 28–30 weeks, with progressive rise toward term. A rise above preconception levels in the third trimester suggests gestational hypertension or preeclampsia. In the postpartum period, BP may rise further in the first 3–5 days due to mobilization of tissue fluid and discontinuation of vasodilatory prostaglandins from the placenta. Peak postpartum BP often occurs on days 3–5. Women with preeclampsia require continued close BP monitoring for at least 72 hours postpartum and often for several weeks.
The threshold for initiating or intensifying antihypertensive therapy in pregnancy has undergone significant guideline evolution.1,2,3 For severe-range hypertension (SBP ≥160 or DBP ≥110 mmHg), urgent antihypertensive treatment within 30–60 minutes is required to prevent maternal stroke and placental abruption; this constitutes a medical emergency and treatment must not be delayed.
For non-severe hypertension in pregnancy (SBP 140–159 or DBP 90–109 mmHg), the CHAP trial (2022) provided pivotal evidence.3 The Chronic Hypertension and Pregnancy trial randomized 2,408 pregnant women with mild chronic hypertension to active treatment (target <140/90 mmHg) versus standard care (treatment only when BP ≥160/105 mmHg). Active treatment reduced the primary composite outcome (preeclampsia with severe features, medically indicated preterm birth <35 weeks, placental abruption, or fetal/neonatal death) by 18% (odds ratio 0.82, 95% confidence interval [CI] 0.74–0.92). The critical finding was that active treatment did not increase the risk of small for gestational age (SGA) birth, which was the principal concern about treating non-severe hypertension in pregnancy. Based on CHAP, current ACOG guidance (2022 update) recommends treating chronic hypertension in pregnancy when SBP ≥140 or DBP ≥90 mmHg, with a target of SBP 120–159 mmHg and DBP 80–104 mmHg.1
While treating hypertension in pregnancy is important, excessive lowering of BP poses a different risk: reduced uteroplacental perfusion. The placenta lacks autoregulation; placental blood flow is directly dependent on maternal BP. Acute or excessive lowering of BP can cause fetal distress, placental insufficiency, and fetal growth restriction. Accordingly, clinicians should not target normal BP (<120/80 mmHg) during pregnancy, should maintain SBP in the 120–159 mmHg range and DBP in the 80–104 mmHg range, and should avoid agents with rapid onset that can cause abrupt drops in BP. Short-acting nifedipine administered sublingually is no longer recommended; oral swallowed nifedipine is acceptable.
Three oral agents have established safety profiles in pregnancy and are considered first-line.1,2,4
Labetalol (oral): A combined non-selective beta-blocker and alpha-1 blocker, labetalol reduces BP through both vasodilation and reduced cardiac output and SVR. Dosing is 100–400 mg twice to three times daily (maximum 2,400 mg/day in divided doses). It crosses the placenta without demonstrated teratogenicity at therapeutic doses, but the neonate should be monitored for bradycardia and hypoglycemia. Its key advantage is the absence of reflex tachycardia, owing to its dual alpha-1 and beta blockade. Labetalol is available in both oral and intravenous (IV) formulations, providing dual utility for chronic management and acute severe episodes. It should be avoided in asthma due to non-selective beta-blockade.
Nifedipine (long-acting formulations): A dihydropyridine calcium channel blocker (CCB), long-acting nifedipine reduces SVR through arteriolar vasodilation without direct cardiac effects. Dosing is 30–90 mg once daily using extended-release formulations only. No teratogenic effects have been identified at therapeutic doses. Only long-acting oral formulations should be used; immediate-release nifedipine given sublingually is contraindicated due to risk of precipitous hypotension and fetal distress. When used concurrently with magnesium sulfate, enhanced hypotension and neuromuscular blockade are possible, as magnesium itself has calcium channel blocking properties; this combination is used clinically but requires close monitoring.6
Methyldopa: A prodrug converted to alpha-methyl-norepinephrine in the central nervous system (CNS), methyldopa reduces central sympathetic outflow through alpha-2 agonism, identical to the mechanism of clonidine. Dosing is 250–500 mg two to three times daily (maximum 3 g/day). It has the longest safety track record of any antihypertensive in pregnancy; long-term follow-up data extending to 7 years have demonstrated no adverse effects on child development.4 Its limitations include sedation and fatigue (the most common reason for discontinuation), positive Coombs test in up to 20% of patients (clinically significant hemolytic anemia is rare), hepatotoxicity (rare but potentially severe), dry mouth, nasal congestion, and depression. Methyldopa remains an important first-line alternative, particularly outside the United States, though it is increasingly replaced by labetalol and long-acting nifedipine due to better tolerability.
Hydralazine (oral): A direct arteriolar vasodilator, oral hydralazine (25–100 mg two to four times daily) is used as a second-line oral agent when first-line agents are insufficient or not tolerated. It has limited fetal safety data compared to first-line agents and is associated with neonatal thrombocytopenia (rare) and drug-induced lupus with prolonged use. It is more commonly used in the IV formulation for acute severe hypertension in pregnancy. Atenolol should be avoided as the preferred beta-blocker in pregnancy due to associations with fetal growth restriction and neonatal bradycardia; if a cardioselective beta-blocker is required, metoprolol is preferred with close fetal monitoring. Amlodipine is less well-studied in pregnancy than nifedipine and is not a preferred CCB; nifedipine is the CCB of choice.
ACE inhibitors and angiotensin receptor blockers (ARBs) are absolutely contraindicated in all trimesters of pregnancy.5 Fetal kidneys depend on the renin-angiotensin-aldosterone system (RAAS) for normal development; angiotensin II-mediated vasoconstriction of the efferent arteriole is essential for maintaining adequate fetal glomerular filtration rate (GFR). Blockade of these functions causes fetal renal dysgenesis and tubular dysplasia, oligohydramnios (which can be severe and lead to fetal demise), limb contractures, pulmonary hypoplasia, neonatal renal failure and anuria, neonatal hypotension, and calvarial hypoplasia. The FDA black box warning requires immediate discontinuation if pregnancy is detected. Women of childbearing potential on ACEi or ARBs must be counseled about contraception and switched to a safe agent immediately upon confirmed pregnancy. Direct renin inhibitors (aliskiren) carry the same contraindication.
Sodium nitroprusside releases cyanide ions during metabolism; fetal cyanide toxicity is a significant risk because the fetal liver has limited capacity for cyanide metabolism. It should be avoided in pregnancy unless no other option is available, and only for the shortest possible duration with cyanide scavenger co-administration. Mineralocorticoid receptor antagonists (spironolactone, finerenone, eplerenone) are generally avoided due to anti-androgenic effects and insufficient human safety data. Thiazide diuretics are not recommended as new agents for hypertension in pregnancy due to theoretical concerns about volume depletion reducing placental perfusion, though they may be continued in women already established on them before pregnancy if essential for volume control.
Acute severe hypertension in pregnancy is defined as SBP ≥160 mmHg or DBP ≥110 mmHg confirmed on two measurements at least 4 hours apart, or sooner if clinically severe. Treatment within 30–60 minutes is required to prevent maternal hemorrhagic stroke and placental abruption.1,2
Three agents are used for acute severe hypertension in pregnancy.1,2,6 IV labetalol is administered as 20 mg IV over 2 minutes; if the response is inadequate, 40 mg IV is given after 10 minutes, then 80 mg IV every 10 minutes (maximum cumulative dose 300 mg per episode). Onset is 5–10 minutes; duration is 3–6 hours. Its advantages include titratable response, reduction in BP without reflex tachycardia, extensive obstetric experience, and safety for the fetus. It is contraindicated in asthma, significant bradycardia, and decompensated heart failure. Fetal heart rate and maternal heart rate should be monitored continuously (target: avoid heart rate [HR] <60 bpm).
Oral nifedipine (immediate-release, swallowed, not sublingual) is given as 10 mg orally, repeated in 20–30 minutes if SBP remains ≥160 or DBP ≥110 mmHg, to a maximum of 30 mg per episode. Onset is 20–30 minutes. The critical distinction is that this is immediate-release nifedipine given by mouth and swallowed, not administered sublingually; sublingual administration produces a precipitous, unpredictable BP drop and is not recommended. Concurrent magnesium sulfate use may enhance hypotension and requires close monitoring.
IV hydralazine is administered as 5–10 mg IV bolus, repeated every 20–30 minutes (maximum 20 mg per episode). Its onset is variable (10–30 minutes) and less predictable than labetalol or nifedipine. Disadvantages include unpredictable response, reflex tachycardia, and more adverse effects including headache, flushing, and palpitations. It is considered a third-line option when labetalol and nifedipine are unavailable or contraindicated. ACOG considers all three acceptable first-line options for acute severe hypertension in pregnancy.1
Magnesium sulfate is the cornerstone of seizure prophylaxis and treatment in severe preeclampsia and eclampsia.1,2 Its anticonvulsant mechanism involves blockade of N-methyl-D-aspartate (NMDA) glutamate receptors in the CNS, reduction of neuronal excitability, and cerebral vasodilation (magnesium is a physiological calcium antagonist). It causes a modest secondary reduction in BP, insufficient for antihypertensive management; dedicated antihypertensive therapy must proceed in parallel.
Dosing: loading dose of 4–6 g IV over 15–20 minutes, followed by maintenance of 1–2 g/hour IV continuous infusion, continued for 24–48 hours postpartum in patients with severe preeclampsia or eclampsia. The therapeutic window is relatively narrow: the therapeutic range is 4–7 mEq/L; loss of deep tendon reflexes (patellar) occurs at 7–10 mEq/L and represents the earliest clinical sign of toxicity; respiratory depression occurs at 10–13 mEq/L; cardiac arrest occurs at >15 mEq/L. Monitoring requires hourly assessment of deep tendon reflexes, respiratory rate (maintain ≥12 breaths/min), and urine output (maintain ≥25 mL/hour; magnesium is renally excreted). The antidote for magnesium toxicity is calcium gluconate 1 g IV (10 mL of 10% solution) over 3 minutes, which reverses respiratory depression and cardiac toxicity.
BP commonly rises in the first 3–5 days postpartum due to fluid mobilization from the extravascular compartment into the intravascular space (particularly pronounced after magnesium sulfate infusion), loss of the vasodilatory influence of the placenta, and hormonal changes associated with initiation of breastfeeding. Monitoring requirements include continued BP surveillance for at least 72 hours after delivery in all women with hypertensive disorders of pregnancy, and 3–7 days monitoring in women with severe preeclampsia. Postpartum eclampsia can occur up to 4 weeks after delivery; patients must be educated to present immediately for severe headache, visual changes, or confusion.
Most antihypertensives used in pregnancy are compatible with breastfeeding.7 Preferred agents include labetalol (low transfer into breast milk, monitor neonate for bradycardia and hypoglycemia), long-acting nifedipine (low transfer, no adverse neonatal effects reported), and methyldopa (low transfer, historically considered safe, though maternal sedation may reduce breastfeeding effectiveness). An important shift from pregnancy rules: captopril and enalapril, specifically, are considered compatible with breastfeeding in full-term neonates due to low breast milk transfer and absence of reported neonatal adverse effects. These specific ACE inhibitors (ACEi) should be avoided in premature neonates due to reduced renal clearance. Women who needed to stop ACEi or ARBs during pregnancy can typically resume a breastfeeding-compatible ACEi postpartum if indicated for renoprotection such as in chronic kidney disease (CKD) or diabetic nephropathy. ARBs and losartan have insufficient breastfeeding safety data and are generally avoided; spironolactone is generally avoided due to the presence of the active metabolite canrenone in breast milk.
Women who have had preeclampsia or other hypertensive disorders of pregnancy carry substantially elevated long-term cardiovascular risk: twice the lifetime risk of cardiovascular disease, four times the risk of hypertension, twice the risk of stroke, and significantly elevated risk of CKD.10,13 These women should be identified, counseled about their long-term risk, and followed with regular cardiovascular risk screening and BP monitoring. Lifestyle modification and antihypertensive therapy for persistent postpartum hypertension should follow standard evidence-based guidelines.
American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237–e260.
doi:10.1097/AOG.0000000000003891Magee LA, Maguire PJ, Bhatt M, et al. ISSHP classification, diagnosis, and management recommendations for international practice. Pregnancy Hypertens. 2022;27:148–169.
doi:10.1016/j.preghy.2021.09.008Tita AT, Szychowski JM, Boggess K, et al. Treatment for mild chronic hypertension during pregnancy (CHAP trial). N Engl J Med. 2022;386(19):1781–1792.
doi:10.1056/NEJMoa2201295Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647–649.
doi:10.1016/S0140-6736(82)92109-9Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists. Hypertension. 2012;60(2):444–450.
doi:10.1161/HYPERTENSIONAHA.111.188235Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy (CHIPS trial). N Engl J Med. 2015;372(5):407–417.
doi:10.1056/NEJMoa1404595Hale TW, Rowe HE. Medications and Mothers' Milk. 17th ed. Springer Publishing; 2017. ISBN:9780826190567
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248.
doi:10.1016/j.jacc.2017.11.006Magee LA, von Dadelszen P, Bohun CM, et al. Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study. J Obstet Gynaecol Can. 2003;25(5):372–382.
doi:10.1016/S1701-2163(16)30201-3Mol BWJ, Roberts CT, Thangaratinam S, et al. Pre-eclampsia. Lancet. 2016;387(10022):999–1011.
doi:10.1016/S0140-6736(15)00070-7Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103(5 Pt 1):981–991.
doi:10.1097/01.AOG.0000126245.26069.61Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071.
doi:10.1097/HJH.0000000000003480Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24–43.
doi:10.1161/HYPERTENSIONAHA.117.10803Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36(5):416–441.
doi:10.1016/S1701-2163(15)30588-0Bramham K, Parnell B, Nelson-Piercy C, et al. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ. 2014;348:g2301.
doi:10.1136/bmj.g2301